Global Generic Injectable Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Generic Injectable Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Generic injectable drugs refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

According to our (Global Info Research) latest study, the global Generic Injectable Drugs market size was valued at US$ 32690 million in 2023 and is forecast to a readjusted size of USD 41260 million by 2030 with a CAGR of 3.4% during review period.

In the segment of generic sterile injectable drugs, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

This report is a detailed and comprehensive analysis for global Generic Injectable Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Generic Injectable Drugs market size and forecasts, in consumption value ($ Million), 2019-2030

Global Generic Injectable Drugs market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Generic Injectable Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030

Global Generic Injectable Drugs market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Generic Injectable Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Generic Injectable Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Generic Injectable Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Generic Injectable Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Small Molecule
Large Molecule

Market segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases

Market segment by players, this report covers
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Generic Injectable Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Generic Injectable Drugs, with revenue, gross margin, and global market share of Generic Injectable Drugs from 2019 to 2024.

Chapter 3, the Generic Injectable Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Generic Injectable Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Generic Injectable Drugs.

Chapter 13, to describe Generic Injectable Drugs research findings and conclusion.